Chang Liu

Dr. Chang Liu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SLShu-Qiang Liu
Shu-Qiang Liu
XCXi-Xi Cheng
Xi-Xi Cheng
SHShuai He
Shuai He
TXTao Xia
Tao Xia
YLYi-Qi Li
Yi-Qi Li
JBJinxin Bei
Jinxin Bei
Super-enhancers (SEs) are expansive cis -regulatory elements known for amplifying oncogene expression across various cancers. However, their role in cervical cancer (CC), a remarkable global malignancy affecting women, remains underexplored. Here we applied integrated epigenomic and transcriptomic profiling to delineate the distinct SE landscape in CC by analyzing paired tumor and normal tissues. Our study identifies a tumor-specific SE at the EFNA1 locus that drives EFNA1 expression in CC. Mechanically, the EFNA1-SE region contains consensus sequences for the transcription factor FOSL2, whose knockdown markedly suppressed luciferase activity and diminished H3K27ac enrichment within the SE region. Functional analyses further underlined EFNA1’s oncogenic role in CC, linking its overexpression to poor patient outcomes. EFNA1 knockdown strikingly reduced CC cell proliferation, migration, and tumor growth. Moreover, EFNA1 cis -interacted with its receptor EphA2, leading to decreased EphA2 tyrosine phosphorylation and subsequent activation of the Src/AKT/STAT3 forward signaling pathway. Inhibition of this pathway with specific inhibitors substantially attenuated the tumorigenic capacity of EFNA1-overexpressing CC cells in both in vitro and in vivo models. Collectively, our study unveils the critical role of SEs in promoting tumor progression through the FOSL2-EFNA1-EphA2-Src/AKT/STAT3 axis, providing new prognostic and therapeutic avenues for CC patients.

25 September 2024 in Environmental Research
Verified
Journal Article
Closed access
CLChang Liu
Chang Liu
GLGuangcong Liu
Guangcong Liu
LYLianzheng Yu
Lianzheng Yu
LHLi Wen Hu
Li Wen Hu
DWDanbo Wang
Danbo Wang


19 November 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XGXiaozhuo Gao
Xiaozhuo Gao
LSLili Sun
Lili Sun
TLTianming Li
Tianming Li
PLPengfei Li
Pengfei Li
CLChang Liu
Chang Liu
MZmei Yan Zhu
mei Yan Zhu
Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment (TME) which promote drug resistance by remodeling the extracellular matrix, generating an immunosuppressive microenvironment, and activating metabolic signaling pathways. Nanomaterials provide an effective method for specifically targeting CAF-mediated drug resistance because of their unique targeted delivery capabilities, responsive release characteristics, and multifunctional integration. Here, we describe the mechanisms underlying the role of CAFs in drug resistance. The types of materials used and design principles are described, and examples of the application of nanomaterials for targeting CAFs are provided. Current challenges and future directions of nanomaterials targeting CAFs for reversing tumor drug resistance are also discussed to provide theoretical support for the development of effective nanotherapies aimed at reversing drug resistance in cancer.


29 December 2025 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
CLChang Liu
Chang Liu
HLHuina Lv
Huina Lv
PLPengfei Li
Pengfei Li